May Soe Thu, Krit Pongpirul, Mawin Vongsaisuwon, Chanida Vinayanuwattikun, Kamonwan Banchuen, Thunnicha Ondee, Sunchai Payungporn, Phanupong Phutrakool, Preecha Nootim, Pajaree Chariyavilaskul, Sarocha Cherdchom, Kulthanit Wanaratna, Nattiya Hirankarn
BACKGROUND: In a pilot study using both cannabidiol (CBD) and tetrahydrocannabinol (THC) as single agents in advanced cancer patients undergoing palliative care in Thailand, the doses were generally well tolerated, and the outcome measure of total symptom distress scores showed overall symptom benefit. The current study aims to determine the intensity of the symptoms experienced by breast cancer patients, to explore the microbiome profile, cytokines, and bacterial metabolites before and after the treatment with cannabis oil or no cannabis oil, and to study the pharmacokinetics parameters and pharmacogenetics profile of the doses...
March 23, 2024: BMC complementary medicine and therapies